- Home
- MA vs NVO Comparison
MA vs NVO Comparison
Compare MA & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | NVO |
|---|---|---|
| Founded | 1966 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.1B | 212.7B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | MA | NVO |
|---|---|---|
| Price | $570.15 | $49.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 11 |
| Target Price | ★ $649.92 | $54.25 |
| AVG Volume (30 Days) | 2.9M | ★ 18.5M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | 0.61% | ★ 2.45% |
| EPS Growth | ★ 18.23 | 10.06 |
| EPS | ★ 15.64 | 3.67 |
| Revenue | $31,474,000,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $19.85 | $7.77 |
| Revenue Next Year | $12.61 | $1.86 |
| P/E Ratio | $36.57 | ★ $13.69 |
| Revenue Growth | 15.60 | ★ 16.64 |
| 52 Week Low | $465.59 | $43.08 |
| 52 Week High | $601.77 | $111.17 |
Technical Indicators
Market Signals| Indicator | MA | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 54.69 |
| Support Level | $535.92 | $46.08 |
| Resistance Level | $559.00 | $49.12 |
| Average True Range (ATR) | 10.13 | 1.15 |
| MACD | 3.35 | 0.49 |
| Stochastic Oscillator | 96.85 | 91.59 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.